TY  - CHAP
M1  - Book, Section
TI  - Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach
A1  - Bueso-Ramos, Carlos
A1  - Garcia-Manero, Guillermo
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
Y1  - 2016
N1  - 
T2  - The MD Anderson Manual of Medical Oncology, 3e
AB  - Myelodysplastic  syndromes  (MDS)  refer  to  a  group  of  hematopoietic  disorders  characterized  by  ineffective  hematopoiesis  and  increased  risk  of  transformation  to  acute  myelogenous  leukemia  (AML).  Most  patients  with  MDS  succumb  to  causes  related  to  the  disease.  The  median  age  of  patients  with  MDS  is  70  to  75  years.  It  is  likely  that  environmental  factors  play  an  important  role  in  the  pathogenesis  of  this  disease.  Myelodysplastic  syndromes  are  classified  according  to  the  World  Health  Organization  (WHO)  criteria,  and  a  number  of  prognostic  scores  can  be  used  to  calculate  survival  and  risk  of  transformation.  Cytogenetic,  genomic,  and  epigenetic  alterations  are  common  in  MDS  and  help  in  the  prediction  of  prognosis  and  potentially  in  the  selection  of  therapy.  Over  the  last  decade,  we  have  witnessed  significant  improvements  in  supportive  care  and  therapeutic  modalities  for  patients  with  MDS.  These  include  growth  factors,  immune  modulatory  agents  (lenalidomide),  and  hypomethylating  agents  (5-azacitidine  and  decitabine).  We  also  better  understand  patient  subgroups,  such  as  those  with  hypomethylating  failure  disease.  In  this  chapter,  we  summarize  our  knowledge  of  MDS  and  the  treatment  approach  we  use  at  MD  Anderson  Cancer  Center.  
SN  - 
PB  - McGraw-Hill Medical
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1126740117
ER  -